Setara Biosciences has raised $90 million in Series A financing to advance a pipeline of precision medicines targeting rare genetic diseases and potentially broader indications.
The company was created following Jazz Pharmaceuticals’ acquisition of Actio Biosciences for Actio’s lead program, ABS-1230, which is being developed for KCNT1-related epilepsy.
Setara will continue developing the remaining Actio pipeline.
Investors in the Series A include Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures, and Jazz Pharmaceuticals.
Setara’s lead program is STAR-0871, formerly known as ABS-0871.
The investigational oral small-molecule drug inhibits TRPV4 and is being developed initially for Charcot-Marie-Tooth disease type 2C and overactive bladder.
CMT2C is a rare inherited neuromuscular disorder caused by gain-of-function mutations in the TRPV4 gene.
Setara estimates the condition affects approximately 2,500 people in the U.S.
The company said STAR-0871 is designed to selectively inhibit TRPV4 and directly address the underlying biological cause of CMT2C.
Setara has completed the healthy volunteer portion of a Phase 1 clinical trial.
The company plans to begin a Phase 1b study called THERON in patients with CMT2C during 2027.
STAR-0871 has received Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the U.S. Food and Drug Administration.
Setara also intends to begin a Phase 2a study of the drug in patients with overactive bladder, a condition affecting tens of millions of people in the U.S.
Beyond STAR-0871, the company is developing early-stage programs targeting genetic epilepsies and broader indications including migraine.
Setara is led by Actio co-founder David Goldstein, who will serve as president and executive chair.
KEY QUOTES:
“Setara allows us to take the next step in our journey, to carry forward a pipeline of promising programs for rare diseases, with the potential to ultimately reach much broader patient populations.”
David Goldstein, Ph.D., Co-Founder, President And Executive Chair Of Setara Biosciences
“Setara brings together experienced operators, a compelling foundation in human genetics, and a promising pipeline grounded in strong biological rationale.”
Jason Fuller, Ph.D., Board Member Of Setara Biosciences And Partner At Deerfield Management

